Loredana Vesci

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Cancer Treatment. Top assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Instituto Nazionale Per Lo Studio E La Cura Dei Tumori. Active years: 2003-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Loredana Vesci. Retrieved from https://idiyas.com/inventor/loredana-vesci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 5.6

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Pomezia, IT (2009)
Rome, IT (2003 - 2016)

Company Filing History:

17 out of 343

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

patents

3 out of 14

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

patents

1 out of 3

Instituto Nazionale Per Lo Studio E La Cura Dei Tumori

patents

4. 1 out of 3

Sigma-Tau Research Switzerland S.a.

patents

where one patent can have more than one assignee

Years Active: 2003-2016

Loading Chart...

Areas of Expertise:

Aryl Triazole Compounds

Anticancer Drugs

Therapeutic Combinations

HDAC Inhibitors

Iminocamptothecin Derivatives

Pediatric Tumors

Retinoid Derivatives

Indole Derivatives

Drug-Resistant Tumors

Cinnamic Acid Derivatives

Cyclic Peptides

L-Carnitine Derivatives

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9302998 - Aryl triazole compounds with antitumoural activity (2016-04-05),

2. 9023861 - Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents (2015-05-05),

3. 8975248 - Combinations of therapeutic agents for treating cancer (2015-03-10),

4. 8927533 - Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments (2015-01-06),

5. 8853233 - Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives (2014-10-07),

6. 8829021 - Treatment of pediatric tumors (2014-09-09),

7. 8101793 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities (2012-01-24),

8. 8053460 - Indole derivatives having antitumor activity (2011-11-08),

9. 7888368 - Treatment of drug-resistant tumors (2011-02-15),

10. 7816386 - Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents (2010-10-19),

11. 7728039 - Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives (2010-06-01),

12. 7705012 - Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents (2010-04-27),

13. 7635719 - Use of adamatyl methoxydiphenyl propenoic acid for the treatment of acne (2009-12-22),

14. 7612081 - 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups (2009-11-03),

15. 7589099 - 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists (2009-09-15),

Title: Loredana Vesci: Innovator in Antitumor Research

Introduction: Loredana Vesci is a prominent inventor based in Rome, Italy, known for her significant contributions to the field of antitumor research. With a total of 18 patents to her name, she has made remarkable strides in developing innovative compounds aimed at combating cancer.

Latest Patents: Among her latest patents is the invention of aryl triazole compounds with antitumoral activity. This invention focuses on aryl triazole derivatives that inhibit the molecular chaperone heat shock protein 90 (Hsp90), which is a potential target in cancer treatment. Additionally, she has developed an anticancer combination of artemisinin-based drugs and other chemotherapeutic agents, demonstrating medium to strong synergism in various cancer models, particularly in non-small cell lung cancer (NSCL).

Career Highlights: Loredana has worked with notable companies in the pharmaceutical industry, including Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. and Istituto Nazionale per lo Studio e la Cura dei Tumori. Her work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations: Throughout her career, Loredana has collaborated with esteemed colleagues such as Claudio Pisano and Giuseppe Giannini. These partnerships have fostered innovation and contributed to the success of her research endeavors.

Profile summary based on public USPTO records.